无自主神经功能障碍的多系统萎缩:一项尸检确诊研究
该多中心队列分析140例尸检确诊的多系统萎缩(MSA)患者,58%初始无自主神经功能障碍,仅9%最终随访时仍未出现。无自主神经障碍者病程显著更长(8.1±2.1年 vs 6.3±2.6年,p=0.035),且小脑起病比帕金森起病更快进展至多系统受累。
要点
- MDS-MSA标准允许仅凭运动症状诊断MSA,约9%尸检确诊患者始终无自主神经障碍。
- 无自主神经障碍的MSA患者病程更长(8.1±2.1年 vs 6.3±2.6年,p=0.035)。
- 小脑起病者比帕金森起病者更快出现第二个症状群(2.0 vs 3.4年,p<0.05)。
核心结论
- MDS-MSA标准扩展了诊断范围,识别出运动症状为主且病程可能更慢的MSA亚组。
研究设计与样本
- 多中心队列分析140例尸检确诊的MSA患者,平均起病年龄62.3±8.9岁,44%为女性。
- 通过标准化病历回顾收集临床数据,按MDS-MSA标准分类,并按初始症状群分组追踪症状演变。
- 统计分析采用ANOVA、t检验、Welch t检验和χ2检验,显著性水平p<0.05。
主要发现
- 81例(58%)初始无自主神经障碍,其中57例仅有帕金森综合征,17例仅有小脑综合征,7例两者兼有。
- 最终随访时12例(9%)仍未出现自主神经障碍,其病程(8.1±2.1年)显著长于匹配的有自主神经障碍者(6.3±2.6年;p=0.035)。
- 51%的患者最终出现全部3个症状群,小脑起病者进展至第二个症状群的中位间隔为2.0年,帕金森起病者为3.4年(p<0.05)。
临床怎么用
- 临床遇到仅有运动症状的MSA疑诊患者时,应认识到部分患者可长期无自主神经障碍,避免过早排除诊断。
- 对无自主神经障碍的MSA患者,需注意其病程可能更长,自然史研究和干预试验应纳入此类患者。
局限性
- 回顾性数据收集可能引入偏倚。
- 症状记录可能存在中心间差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by 3 core symptom complexes: parkinsonism, cerebellar syndrome, and dysautonomia. Recent Movement Disorder Society (MDS) criteria allow for the clinical diagnosis of MSA based solely on motor symptoms, without requiring dysautonomia. This study aimed to evaluate the frequency and disease trajectory of MSA patients without dysautonomia compared with those with autonomic involvement. METHODS: A multicenter cohort of autopsy-confirmed patients with MSA was analyzed for demographic characteristics, symptom onset, and progression of parkinsonism, cerebellar syndrome, and dysautonomia. Clinical data were collected through standardized chart reviews across participating centers and categorized using the MDS-MSA criteria. Patients were grouped according to their initial symptom complex and tracked for the evolution of additional symptoms. Analyses included time to development of further symptom complexes, age at symptom onset, disease duration, and phenotype at the last recorded visit. Patients with motor symptoms only were matched to patients with similar demographics but with dysautonomia. Statistical methods included ANOVA, t tests, Welch t tests, and χ2 tests, with significance set at p < 0.05. RESULTS: Among 140 patients (mean age at onset 62.3 ± 8.9 years; 44% female), 81 (58%) initially presented without dysautonomia (57 with parkinsonism only, 17 with cerebellar syndrome only, 7 with both). At final follow-up, 12 patients (9%) had not developed dysautonomia. These patients showed significantly longer disease duration (mean 8.1 ± 2.1 years) than matched patients with dysautonomia (mean 6.3 ± 2.6 years; p = 0.035). Overall, 51% of patients developed all 3 symptom complexes. Patients with cerebellar onset progressed more rapidly to multisystem involvement than those with parkinsonian onset (mean interval to second symptom: 2.0 vs 3.4 years; p < 0.05). DISCUSSION: The MDS-MSA criteria expand the diagnostic scope by identifying a motor-only subgroup with a distinct and potentially slower disease course. These findings underscore the importance of including motor-only patients in natural history and interventional studies. Limitations include retrospective data collection and potential variability in symptom documentation.
引用
- Wilkens I, Bebermeier S, Heine J, et al. Multiple System Atrophy Without Dysautonomia: An Autopsy-Confirmed Study. Neurology. 2025. PMID: 41232058. doi:10.1212/WNL.0000000000214316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。